Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 10Gastro-enteropancreatic neuroendocrine tumor 4Pheochromocytoma 2Paraganglioma 2Vipoma 1Thymus Neoplasms 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Lymphoma 1Insulinoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Leucovorin 3Fluorouracil 3Everolimus 3vatalanib 2Trastuzumab 2Streptozocin 2Oxaliplatin 2Doxorubicin 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Omeprazole 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gefitinib 1Floxuridine 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡